Advanced search

Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo

(1997) EUROPEAN HEART JOURNAL. 18(4). p.643-648
Author
Organization
Abstract
Aims: A randomized, double-blind study with a high dose of digoxin administered intravenously for conversion of atrial fibrillation (not due to haemodynamic alterations) to sinus rhythm, and for rate control in converters and non-converters was set up. Outcome measures were conversion within 12 h; lime to conversion; early rate control; and stable slowing within 12 h. Methods: We studied 40 patients with recent onset (<1 week) atrial fibrillation; controls received saline intravenously, the other patients digoxin 1.25 mg. Results: One patient converted before digoxin administration. Conversion occurred in 9/19 patients on digoxin and in 8/20 on placebo (ns). The mean time to conversion tended to be shorter only for digoxin. Two late conversions on placebo were observed within 24 h. Heart rate during atrial fibrillation decreased after 30 min for converters and non-converters (P<0.05). For all patients on digoxin, heart rate after 30 min was lower compared to baseline (P<0.002) and to placebo (P<0.02). Persistent, stable slowing occurred only in 3/10 non-converters on digoxin (P<0.05), and two patients developed bradyarrhythmias. QTc was shortened immediately after conversion in all patients. Converters had baseline characteristics similar to those of non-converters. Conclusions: Intravenous digoxin offers no substantial advantages over placebo in recent onset atrial fibrillation with respect to conversion, and provides weak rate control.
Keywords
atrial fibrillation, arrhythmias, bradycardia, digoxin, heart rate, QT interval, HEART-FAILURE, DRUG-THERAPY, TIME, FLUTTER, TRIALS, ONSET

Citation

Please use this url to cite or link to this publication:

Chicago
Jordaens, Luc, Jan Trouerbach, Paul Calle, René Tavernier, E Derycke, P Vertongen, B Bergez, and Y Vandekerckhove. 1997. “Conversion of Atrial Fibrillation to Sinus Rhythm and Rate Control by Digoxin in Comparison to Placebo.” European Heart Journal 18 (4): 643–648.
APA
Jordaens, Luc, Trouerbach, J., Calle, P., Tavernier, R., Derycke, E., Vertongen, P., Bergez, B., et al. (1997). Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. EUROPEAN HEART JOURNAL, 18(4), 643–648.
Vancouver
1.
Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. EUROPEAN HEART JOURNAL. 1997;18(4):643–8.
MLA
Jordaens, Luc, Jan Trouerbach, Paul Calle, et al. “Conversion of Atrial Fibrillation to Sinus Rhythm and Rate Control by Digoxin in Comparison to Placebo.” EUROPEAN HEART JOURNAL 18.4 (1997): 643–648. Print.
@article{182655,
  abstract     = {Aims: A randomized, double-blind study with a high dose of digoxin administered intravenously for conversion of atrial fibrillation (not due to haemodynamic alterations) to sinus rhythm, and for rate control in converters and non-converters was set up. Outcome measures were conversion within 12 h; lime to conversion; early rate control; and stable slowing within 12 h. 
Methods: We studied 40 patients with recent onset (<1 week) atrial fibrillation; controls received saline intravenously, the other patients digoxin 1.25 mg. 
Results: One patient converted before digoxin administration. Conversion occurred in 9/19 patients on digoxin and in 8/20 on placebo (ns). The mean time to conversion tended to be shorter only for digoxin. Two late conversions on placebo were observed within 24 h. Heart rate during atrial fibrillation decreased after 30 min for converters and non-converters (P<0.05). For all patients on digoxin, heart rate after 30 min was lower compared to baseline (P<0.002) and to placebo (P<0.02). Persistent, stable slowing occurred only in 3/10 non-converters on digoxin (P<0.05), and two patients developed bradyarrhythmias. QTc was shortened immediately after conversion in all patients. Converters had baseline characteristics similar to those of non-converters. 
Conclusions: Intravenous digoxin offers no substantial advantages over placebo in recent onset atrial fibrillation with respect to conversion, and provides weak rate control.},
  author       = {Jordaens, Luc and Trouerbach, Jan and Calle, Paul and Tavernier, René and Derycke, E and Vertongen, P and Bergez, B and Vandekerckhove, Y},
  issn         = {0195-668X},
  journal      = {EUROPEAN HEART JOURNAL},
  keywords     = {atrial fibrillation,arrhythmias,bradycardia,digoxin,heart rate,QT interval,HEART-FAILURE,DRUG-THERAPY,TIME,FLUTTER,TRIALS,ONSET},
  language     = {eng},
  number       = {4},
  pages        = {643--648},
  title        = {Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo},
  volume       = {18},
  year         = {1997},
}